Biotech buyouts that included contingent-value rights: • SNY-GENZ (2011) • CELG-Abraxis (2010) • LGND-Metabasis (2010) • LGND-Neurogen (2009) • ENDP-Indevus (2009) • MDCO-Targanta (2009) • Fresenius-APP Pharma (2008) • LGND-Pharmacopeia (2008) • VPHM-Lev (2008) • OSIP-Cell Pathways (2003)